Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
RESMED INC (RMD)ASX AI Signals has generated 2 signal(s) for RMD during the last 90 days, indicating Moderate trading activity
Latest RMD Signals | |
| 03/06/2026 | SELL |
| 23/04/2026 | SELL |
| 06/03/2026 | BUY |
RMD Share Price | |
| Current Price | $30.500 |
| 52 Week High | $44.942 |
| 52 Week Low: | $25.840 |
| Trading at (% of 52 Week High) | 67.87% |
ResMed Inc (ASX: RMD) is a global company that develops, manufactures, and markets medical devices and cloud-connected software for the diagnosis and treatment of sleep apnea, chronic obstructive pulmonary disease (COPD), and other chronic respiratory conditions. The company’s products include ventilators, CPAP machines, masks, and digital health tools designed to improve patient care and outcomes. ResMed serves healthcare providers and patients worldwide.
The Health Care Equipment & Services sector on the ASX includes companies that produce medical devices, equipment, and supplies, as well as those providing healthcare-related services. This sector covers a wide range of products such as surgical instruments, diagnostic machines, and health monitoring devices. It also includes businesses involved in healthcare management, medical laboratories, and support services. These companies play a key role in supporting hospitals, clinics, and other healthcare providers to improve patient care. The sector is influenced by factors like technological advances, regulatory changes, and demand for healthcare services.
The SELL recommendation for RESMED INC (RMD) is supported by moderate bearish signals, but the overall market position and company fundamentals suggest caution. The confidence level reflects a balanced view considering potential risks and some underlying strengths.
Earnings To Watch: ResMed (RMD) Reports Q1 Results Tomorrow
Medical device company ResMed (NYSE:RMD) will be announcing earnings results tomorrow after market close. Here’s what to look for.
ResMed beat analysts’ revenue expectations by 1% last quarter, reporting revenues of $1.28 billion, up 10.3 Resmed, Inc.
Former Illumina, MSCI, and Moody’s executive brings extensive experience leading engagement with the global investment community
SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care del The market expects InMode (INMD) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its ne Wall Street analysts forecast that ResMed (RMD) will report quarterly earnings of $2.36 per share in its upcoming release, pointing to a year-over-year increase of 10.8%. It is anticipated that revenues will amount to $1.28 billion, exhibiting an increase of 7.3% compared to the year-ago quarter.
T Wall Street expects a year-over-year increase in earnings on higher revenues when ResMed (RMD) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock pLatest RESMED INC(RMD) News
Earnings To Watch: ResMed (RMD) Reports Q1 Results Tomorrow
Resmed Names Salli Schwartz as Chief Investor Relations Officer
Earnings Preview: InMode (INMD) Q1 Earnings Expected to Decline
What Analyst Projections for Key Metrics Reveal About ResMed (RMD) Q3 Earnings
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial